statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities...

Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aditxt  in pact to acquire Appili Therapeutics for 5.6c per share

Aditxt, Inc. (Aditxt or the Company) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive...

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Appili Therapeutics signs definitive agreement to be acquired by Aditxt

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR...

Appili Therapeutics Signs Definitive Agreement  to be Acquired by Aditxt, Inc.

Aditxt's wholly owned subsidiary, Adivir, Inc. will acquire all issued and outstanding Class A common shares of Appili in the transaction. Appili has developed FDA-approved Likmez (previously...

Why Aditxt Stock Is Volatile Today

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 PR Newswire SAN DIEGO, March 27, 2024 -- Third Consecutive Year of...

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Evofem Negotiates Improved Rebate for Hormone-Free 'In the Moment' Contraceptive PHEXXI with Medi-Cal Evofem Negotiates Improved Rebate for Hormone-Free 'In the Moment&quot...

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy For Women Using GLP-1...

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 PR...

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Volume	44,596.00
52-Wk High	$68.08
52-Wk Low	$2.14

ADTX Aditxt Inc

About

Feed

News

Fundamentals